Articles & Issues
- Language
- English
- Conflict of Interest
- In relation to this article, we declare that there is no conflict of interest.
-
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/3.0) which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright © KIChE. All rights reserved.
All issues
THE SELECTIVE DELIVERY OF ANTICANCER AGENTS USING TARGET-SENSITIVE LIPOSOMES
Korean Journal of Chemical Engineering, July 1996, 13(4), 393-398(6), 10.1007/BF02705967
Download PDF
Abstract
Target-sensitive (TG-S) liposomes having modified antibodies on their surface were employed to study the release of calcein and the selective delivery of the anticancer agents, doxorubicin(DOX) and methotrexate (MTX). The release of calcein from TG-S liposome occurred when the various target cells were contacted with liposomes and it was proportionally increased with the increase of antibody affinity to the target cells. Increasing the concentration of antigen molecules (major histocompatibility, MHC) on the surface of RMA-S, the release of calcein and drugs from TG-S liposomes was only induced above a threshold density of surface antigen on the target cell membrane. The growth inhibition of specific target cells by the liposomal drugs was always stronger than that of the non-specific ones. For specific target cells, the IC50 of liposomal DOX was about 2 times greater than that of free DOX, on the while, for non-specific target cells, more than 5 times. This indicates that the liposomal drugs were transferred preferentially to the specific target cells than the non-specific ones. Based on this phenomenon, the TG-S liposomal MTX were also applied for the selective elimination of the specific target cells in the mixed culture of specific and non-specific target cells.
References
Ahmad I, Longenecker M, Samuel J, Allen TM, Cancer Res., 53, 1484 (1993)
ATCC Catalog of Cell Lines and Hybridomas 7th ed., 370 (1992)
Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J, J. Exp. Med., 180, 1471 (1994)
Heath TD, Montgomery JA, Piper JR, Papahadjopoulos D, Proc. National Acad. Sci. USA, 80, 1377 (1983)
Ho RJY, Rouse BT, Huang L, Biochem. Biophys. Res. Commun., 138, 931 (1986)
Ho RJY, Rouse BT, Huang L, Biochemistry, 25, 5500 (1986)
Ho RJY, Rouse BT, Huang L, J. Biol. Chem., 262, 13973 (1987)
Hosken NA, Bevan MJ, J. Exp. Med., 175, 719 (1992)
Huang L, Biochemistry, 24, 29 (1985)
Johnstone A, Thorpe R, "Immunochemistry in Practice," 253 Blackwell Sci. Pub., Oxford (1982)
Leserman LD, Barbet J, Kourilsky F, Weinstein JN, Nature, 288, 602 (1980)
Mosmann T, J. Immunol. Method, 65, 55 (1983)
Pinnaduwage P, Huang L, "Target-sensitive Liposomes for Potential Therapeutic Applications," Liposome Technology, Gregoriadis G. ed. 2nd ed., Vol. III, CRC Press, London (1993)
Yang JM, Yang JW, Kim JD, Choe TB, Korean J. Biotechnol. Bioeng., 10, 428 (1995)
ATCC Catalog of Cell Lines and Hybridomas 7th ed., 370 (1992)
Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J, J. Exp. Med., 180, 1471 (1994)
Heath TD, Montgomery JA, Piper JR, Papahadjopoulos D, Proc. National Acad. Sci. USA, 80, 1377 (1983)
Ho RJY, Rouse BT, Huang L, Biochem. Biophys. Res. Commun., 138, 931 (1986)
Ho RJY, Rouse BT, Huang L, Biochemistry, 25, 5500 (1986)
Ho RJY, Rouse BT, Huang L, J. Biol. Chem., 262, 13973 (1987)
Hosken NA, Bevan MJ, J. Exp. Med., 175, 719 (1992)
Huang L, Biochemistry, 24, 29 (1985)
Johnstone A, Thorpe R, "Immunochemistry in Practice," 253 Blackwell Sci. Pub., Oxford (1982)
Leserman LD, Barbet J, Kourilsky F, Weinstein JN, Nature, 288, 602 (1980)
Mosmann T, J. Immunol. Method, 65, 55 (1983)
Pinnaduwage P, Huang L, "Target-sensitive Liposomes for Potential Therapeutic Applications," Liposome Technology, Gregoriadis G. ed. 2nd ed., Vol. III, CRC Press, London (1993)
Yang JM, Yang JW, Kim JD, Choe TB, Korean J. Biotechnol. Bioeng., 10, 428 (1995)
